Researchers Discover Signatures Predicting Therapeutic Applications & Toxicity of Chemicals
To predict the effects of a compound on the human body, one needs to assess its biological activity, which requires pinpointing the affected biological processes within cells. Considering that living cells comprise myriads of biological processes, this is a daunting task.
Researchers from Attagene and the U.S. Environmental Protection Agency have found a new, straightforward approach to the assessment of the biological activities of chemicals.
Using Attagene's proprietary technology, the FACTORIAL™, the researchers analyzed perturbations of cellular signaling pathways that regulate gene expression. They found that disruption of different biological processes produced reproducible patterns of perturbation in cell signaling. Moreover, chemicals disrupting the same bioprocess all produced identical patterns, regardless of where and how they interfered. Thus, the researchers called those patterns 'invariant signatures of bioactivities'.
Using the invariant signatures, the researchers were able to accurately identify compounds with specified bioactivities among thousands of uncharacterized chemicals. Moreover, they showed that this approach permitted a straightforward identification of multiple bioactivities of polypharmacological drugs.
The new approach has important ramifications for the drug development process and toxicity testing. The new signatures offer simple and cost-effective solutions to drug discovery, selection of safe drug candidates and to repurposing of existing drugs for new applications. Furthermore, the new approach enables assessing underlying mechanisms for the toxicity of environmental chemicals.
"Traditional genetic approaches deduce the bioactivity of chemicals by assessing changes in gene expression. These predictions are often imprecise and require complex computations," says senior author and Attagene CEO Dr. Sergei Makarov. "Instead, we assessed the cellular signaling pathways that regulate gene expression," Makarov says. "As there are fewer pathways than genes, these signatures are easy to interpret."
"We have identified specific signatures for many bioactivities, including mitochondria, proteasome and HDAC inhibitors, DNA-damaging agents, and cytoskeleton disruptors," says the first author Dr. Alexander Medvedev, Attagene's Director of Research and Development. "Those signatures define the most sought-after classes of anticancer drugs. And this diversity indicates that we will find specific signatures for many other therapeutically-relevant bioactivities."
"It has taken a lot of heart and over ten years of work of an amazingly dedicated group of people to develop this approach," added Dr. Makarov.
This research is published in the journal Science Advances.
This article has been republished from materials provided by Attagene. Note: material may have been edited for length and content. For further information, please contact the cited source.